Literature DB >> 1724954

Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies.

R Würzner1, M Schulze, L Happe, A Franzke, F A Bieber, M Oppermann, O Götze.   

Abstract

Three monoclonal antibodies (mabs), two against C5 and one against C6, were identified and characterized. They inhibited the generation of the terminal complement complex (TCC) in serum to over 90% as assayed by a sensitive ELISA based on a neoepitope-specific mab, which recognized TCC-integrated C9. The haemolytic function of the TCC was markedly reduced by all three mabs implying that they are directed to epitopes on C5 and C6 which are essential for TCC formation in both the fluid phase and on erythrocyte membranes. Since the generation of C5a was also impaired by these mabs, they may serve as tools in investigations of the sequelae of the generation of C5a and of TCC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724954     DOI: 10.1159/000463204

Source DB:  PubMed          Journal:  Complement Inflamm        ISSN: 1012-8204


  24 in total

1.  An abnormal but functionally active complement component C9 protein found in an Irish family with subtotal C9 deficiency.

Authors:  Ann Orren; Ann M O'Hara; B Paul Morgan; Anthony P Moran; Reinhard Würzner
Journal:  Immunology       Date:  2003-03       Impact factor: 7.397

Review 2.  Inhibition of complement as a therapeutic approach in inflammatory central nervous system (CNS) disease.

Authors:  S R Barnum
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

3.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  Importance of the third thrombospondin repeat of C6 for terminal complement complex assembly.

Authors:  R Würzner; D Mewar; B A Fernie; M J Hobart; P J Lachmann
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

Review 5.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

6.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.

Authors:  C S Rinder; H M Rinder; B R Smith; J C Fitch; M J Smith; J B Tracey; L A Matis; S P Squinto; S A Rollins
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

7.  Glycosylation of IgA is required for optimal activation of the alternative complement pathway by immune complexes.

Authors:  W Zhang; P J Lachmann
Journal:  Immunology       Date:  1994-01       Impact factor: 7.397

8.  Properties of a low molecular weight complement component C6 found in human subjects with subtotal C6 deficiency.

Authors:  A Orren; R Würzner; P C Potter; B A Fernie; S Coetzee; B P Morgan; P J Lachmann
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

9.  Extracts of wheat gluten activate complement via the alternative pathway.

Authors:  D J Unsworth; R Würzner; D L Brown; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1993-12       Impact factor: 4.330

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.